KinoPharma, Inc.

Founded in 2005 and based in Tokyo, Japan, KinoPharma, Inc. operates as a company that conducts research and development of small-molecule drugs for HPV related diseases and severe viral infections, collaborating with academic institutions to create antiviral therapies targeting host factors to suppress virus replication. Founded in 2005 and based in Tokyo, Japan, KinoPharma, Inc. operates as a company that conducts research and development of small-molecule drugs for HPV related diseases and severe viral infections, collaborating with academic institutions to create antiviral therapies targeting host factors to suppress virus replication.

In April 2025, KinoPharma, Inc. raised an undisclosed amount of venture funding from new investor AirTrip. KinoPharma, Inc. focuses on next-generation antiviral medications, primarily targeting human papillomavirus (HPV) infections linked to cervical cancer.

Their pipeline includes a Phase II clinical trial for common warts initiated in June 2023, alongside previous initiatives for cervical dysplasia treatments, specifically in South Korea. Their products serve healthcare providers, hospitals, and clinics, mainly in Japan, with potential plans for expansion into other high-need markets. KinoPharma's revenue is generated through strategic partnerships and clinical trials within the pharmaceutical sector. The company engages in collaborative agreements, like the exclusive option contract with Aska Pharmaceutical Co.

, Ltd. for cervical dysplasia treatments. Revenue streams will include milestone payments and royalties upon product commercialization, reflecting their ongoing development efforts. As of April 2025, the company plans to expand antiviral drug pipeline, strengthen academic partnerships, and accelerate global commercialization efforts.